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Abstract
Background: Schizophrenia is associated with excess mortality and multimorbidity, which is possibly associated
with difficulty in coordinating care for multiple mental and physical comorbidities. We analyzed the receipt by
patients with schizophrenia of 11 types of guideline-concordant care and the association of such care with survival.
Methods: Guideline-concordant care over an 8-year period (financial years 2002 to 2009) was examined in a
nationwide sample of 49,173 male veterans with schizophrenia, who were aged 50 years or older. Administrative
databases from the electronic medical record system of the Veterans Health Administration (VA) provided
comprehensive measures of patient demographics and medical information. Relying on the 2004 American
Psychiatric Association guidelines, patterns in 11 types of care were identified and cluster-analyzed. Care types
included cardiovascular, metabolic, weight management, nicotine dependence, infectious diseases, vision, and
mental health counseling (individual, family, drugs/alcohol, psychiatric medication, and compensated work therapy).
Survival analysis estimated association of care patterns with survival, adjusting for clinical and demographic
covariates.
Results: There was an average of four chronic diseases in addition to schizophrenia in the cohort, notably
hypertension (43%) and dyslipidemia (29%). Three longitudinal trajectories (clusters) were identified: ‘high-
consistent’ (averaging 5.4 types of care annually), ‘moderate-consistent’ (averaging 3.8), and ‘poor-decreasing’
(averaging 1.9). Most veterans were receiving cardiovascular care (67 to 76%), hepatic and renal function assays (79
to 84%), individual counseling (72 to 85%) and psychiatry consults (66 to 82%), with the proportion receiving care
varying by cluster group. After adjustment for age, baseline comorbidity, and other covariates, there was a greater
survival rate for those with poor-decreasing care compared with high-consistent care, and for high-consistent
compared with moderate-consistent care.
Conclusions: Relatively low levels of guideline-concordant care were seen for older VA patients with schizophrenia,
and trajectories of care over time were associated with survival in a non-intuitive pattern. The group with the
lowest and decreasing levels of care was also the oldest, but nonetheless had the best age-adjusted and other
covariate-adjusted survival rates, possibly because they were requiring less care relative to younger, sicker veterans,
and thus their comorbidity burden was markedly lower. Notably, in the group with the sickest individuals (that is
those with the highest comorbidity scores, who were very disabled), receiving guideline-concordant care was
associated with improved survival in adjusted models compared with those patients receiving only moderate levels
of care.
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Background
Premature mortality among individuals with schizophrenia
is well documented in the literature [1,2]. The increased
mortality rates of these individuals is linked to their
increased burden of medical [3,4] and psychiatric [5]
comorbidities. Physical disorders in individuals with schi-
zophrenia account for an estimated 60% of premature
deaths [6], yet, these individuals are less likely to seek
appropriate care and may use medical services intermit-
tently, leading to unresolved medical problems, decreased
treatment adherence, and premature mortality [7], which
might be preventable with appropriate care.
To target the diverse health care needs of individuals
with schizophrenia, the American Psychiatric Association
(APA) outlined in 2004 practice guidelines for appropriate
preventive care [8]. In addition to psychiatric medication
management, the APA guidelines highlight the importance
of comprehensive care for common conditions including
hypertension [9,10], diabetes [11], obesity [12], lipid disor-
ders [6], pulmonary and other infections [13], cardiovascu-
lar disease and metabolic syndrome [14], tobacco and
substance use disorders [15], and liver disease [16].
Whether and which of these types of care are typically
accessed and how they are related to survival remains to
be studied.
Previous research on older patients with schizophrenia
receiving care from the Veterans Health Administration
(VA) noted associations of attendance at primary-care
clinics with improved odds of survival, results that led to a
directive for outreach to patients with schizophrenia who
fail to access care for 12 months or more [3,17,18]. This
study examined veterans with schizophrenia age 50 or
older, receiving care in the VA, to determine whether there
were particular types and patterns of routine outpatient
care that were associated with improved survival, using a
framework of specific care recommendations, over the
8-year period from October 2001 through September 2009.
Methods
Study design
The study was approved by the local institutional review
board (IRB) before initiation. As part of a larger retro-
spective study of late-life healthcare for veterans with
chronic disease [17], veterans diagnosed with schizo-
phrenia and receiving VA care during the fiscal year
(FY) 2002 (FY02; from October 2001 to September
2002) were followed to the end of FY09 using adminis-
trative extracts from the all-electronic medical records
system of the VA.
Study sample
Veterans seeking care from the VA were included in
this study if they were diagnosed with schizophrenia
(International Classification of Disease (ICD)9 code 295,
excluding 295.5) on at least two outpatient or one inpa-
tient dates during FY02, and were at least 50 years old
in that year [19]. Exclusions were: death during FY02
(n = 2,051), female gender (n = 1,773), inconsistent
dates with respect to death (probable data-entry errors;
n = 134), missing data on veteran status (n = 125), and
long-term inpatient status in FY02 (150+ days; n = 24)
[20], leaving 49,173 patients (mean ± SD age 59.6 ± 9.2
years, range 50 to 102) in the cohort.
Measures
Annual care indicators corresponded to APA categories
[8]. Care type was captured from VA outpatient clinic
identifiers (stop codes) and care provision codes (Current
Procedural Terminology (CPT) and Healthcare Common
Procedure Coding System (HCPCS); see Additional file
1). Recommendations for medical care addressed: weight
management, tobacco cessation, infectious diseases (HIV,
hepatitis C, or syphilis), cardiovascular risk (diabetes,
hypertension, dyslipidemia, heart failure), and blood che-
mistries (renal and liver function, hyperprolactinemia).
Eye care was also included, as older people require regu-
lar eye examinations, especially if they have co-occurring
diabetes. Recommended mental health care included:
individual psychotherapy, group counseling, family inter-
ventions, psychiatry medication consults, and drug/alco-
hol care or screening. The APA guidelines discuss the
value of individual, group, and family counseling for
patients with schizophrenia, emphasizing that treatment
delivery must be tailored to the patient, leading to our
selection of these five types of mental health care. Receipt
of any care during a year constituted the meeting guide-
lines for that care type. The indicators were then
summed to assess total annual care (range 0 to 11 for
each year).
Given that antipsychotic treatment is strongly recom-
mended for patients with schizophrenia, and medication
adherence correlates with better outcomes [21], we also
generated mutually exclusive covariates assessing baseline
antipsychotic use: 1) good adherence was indicated by
having the equivalent of 30-day prescriptions of antipsy-
chotics (AP) for at least 10 months annually (10/12 or 83%
adherence); 2) poor adherence was indicated by prescrip-
tions for 1 to 9 months; and 3) irregular antipsychotic
adherence. Irregular adherence was indicated by 0 months
of AP use during the baseline year. Good adherence served
as the reference group for the two indicators of suboptimal
antipsychotic use. Gaps of 3 or more months in antipsy-
chotic use (≤75% adherence) are associated with psychia-
tric readmission [21].
The primary outcome of interest (death) was based on
the date of death as given in the VA Mini-Vital Status file,
which is compiled from four sources using a validated
algorithm for discordant cases. Sohn and colleagues [22]
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reported ~98% sensitivity for the VA file relative to the
National Death Index. Survival was assessed in days.
We also assessed age, race, ethnicity, marital status, and
VA priority score at baseline (FY02). VA priority, based on
disability from a condition attributed to military service,
describes why a veteran qualifies for VA care, and whether
they have co-payments. It is a proxy for both socioeco-
nomic status and disease severity [23]. Priority 1 veterans
have a high level of disability, are often impoverished, and
incur no co-payments for care or prescription medications
in the VA. We contrasted priority 1 against all other prio-
rities for VA care.
The case mix was assessed using the Charlson [24,25]
and Selim [26] comorbidity indices. The Charlson sums
weights for 19 conditions that are correlated with post-
discharge mortality (including myocardial infarct, demen-
tia, diabetes, and diabetes with complications) as imple-
mented in administrative data [27,28]. The Selim sums 30
chronic physical and 6 psychiatric disorders as the Selim
Comorbidity Score; this measure has been validated
against care utilization, costs of care, and mortality [17].
The Charlson and Selim indices do not have high correla-
tion with each other, and capture different aspects of the
patient comorbidity burden.
Analysis
Frequencies and means (standard deviations) were used
to describe the baseline characteristics and types of care
received each year. A cluster analysis uncovered longitu-
dinal patterns in the level and trajectory of the 11 treat-
ment types. For the cluster analysis, patterns among
patients with complete data over the study period (sur-
vivors) were assessed, resulting in three clusters with
eigenvalues of greater than 1 to denote significantly dis-
tinct patterns of care [29]. Patients with censored data
were then examined in seven additional cluster analyses
(one for each year after baseline) using data from all
years before the year of death. For each year, the cen-
sored patterns were compared with the survivor pat-
terns. Decedents were assigned to the survivor care
cluster most similar to their pattern before death
occurred; all decedent clusters had eigenvalues > 1
(graphs of the decedent trajectories are available upon
request).
We examined Kaplan-Meier estimates of the time to
death or to the end of the study (data right-censored)
by care cluster. Both log-rank and Wilcoxon statistics
showed significant differences between the three clusters
(P<0.01). A Cox proportional-hazards regression model
estimated risk-adjusted survival as a function of care
cluster; covariates included age, Charlson and Selim
comorbidity indices, medication adherence indicators,
and VA priority 1 status.
Results
Sample and care descriptive
The Charlson and Selim comorbidity scores were 1.00
(SD ± ± 1.5 and 3.82 (SD ± 2.2, respectively, with an
estimated correlation of r = 0.59 (35% shared variance;
p<0.05). Slightly more than> half (53%) had VA priority
1 status (see Table 1).
In terms of guideline-concordant care for FY02 to
FY09, most of the veterans were receiving cardiovascular
care (67 to 76%), hepatic and renal function assays (79
to 84%), individual counseling (72 to 85%), and psychia-
try consults (66 to 82%). Family counseling, individual
counseling, group counseling, and psychiatry consults
appeared to decrease over time (from 82% with psychia-
tric consults in FY02 to 66% in FY09), whereas cardio-
vascular and drug/alcohol care appeared to increase (see
Figure 1). Only a small proportion of VA patients in
this study had documented care for nicotine dependence
(3 to 6%), weight management (11 to 13%), drug/alcohol
use (13 to 17%), infectious disease (22 to 28%), or eye
care (26 to 35%), or received group (12 to 21%) or
family counseling (3 to 8%),.
Cluster profiles
Individuals with high-consistent care averaged 5.4 types
of care across all years (Figure 2). This was the most
common pattern, evident in the youngest group with
the most comorbidity and the largest proportion of
priority 1 veterans (n = 20,854). This group experienced
26% mortality over the follow-up period (unadjusted
rate). Those with moderate-consistent care averaged 3.8
types of care, and these were a group of veterans with
an unadjusted mortality rate of 36% (n = 18,218). People
in the poor-decreasing trajectory averaged 1.9 types of
care across all years; this group had the oldest patients
(but with a wider variation in age, with SD = 10 years),
but had the least comorbidity and smallest proportion
of priority 1 veterans, and experienced an unadjusted
mortality rate of 31% (n = 10,101). Cancer was relatively
more common in the moderate-consistent care group
whereas cardiovascular diagnoses were highest in the
high-consistent care group (Table 2).
Patients in the high-consistent group consistently
received more types of care over time, including weight
management (18% to 21% per year), infectious disease
(32% to 41%), renal/liver function (95% to 99%), and indi-
vidual counseling (93 94%), compared with those in the
moderate-consistent (6% to 8%, 18% to 22%, 80% to 88%,
and 74% to 82%, respectively) or poor-decreasing groups
(2% to 8%, 6% to 16%, 28% to 65%, and 13% to 72%,
respectively). Overall, there was an apparent increasing
trend from baseline to FY09 in the proportion of patients
receiving cardiovascular care (from 83% to 96%), eye care
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(37% to 55%), drug/alcohol care (20% to 27%) and renal/
liver function care (95% to 99%). However, a decreasing
trend was seen for psychiatric medication consults (91%
to 88%), group counseling (31% to 23%), and family
counseling (11% to 5%). Weight management, nicotine
dependence, and individual counseling appeared fairly
stable across the years. A smaller proportion of patients
in the poor-decreasing group received recommended
treatment across all types of care than in the high-
consistent and moderate-consistent groups. In the poor-
decreasing group, a moderate percentage of patients
initially received several types of recommended care,
but this proportion dropped sharply over time from
baseline to FY09: cardiovascular care dropped from 48%
to 24%, renal/liver function care from 65% to 29%,
psychiatric medication management from 70% to 20%,
and individual counseling from 72% to 24%. In the
poor-decreasing group, the numbers receiving weight-
management care (8% to 2%) and eye care (16% to 7%)
were particularly low.
Mortality models
The relationship between receipt of guideline-concor-
dant care and mortality rate was examined with and
without adjustment for baseline characteristics, using
Cox proportional-hazards models. In the unadjusted
model, the estimated probability of surviving at least 5
years was 0.85 for those in the high-consistent group,
0.77 in the moderate-consistent groups, and 0.82 in the
poor-decreasing group. Survival from Oct 2001 until
death averaged 7.1 years for the high-consistent, 6.6
years for the moderate-consistent, and 6.9 years for the
poor-decreasing group. The 25th percentile of survival
time was estimated at 7.6 years for the high-consistent
group, 5.5 years for the moderate-consistent group, and
6.3 years for the poor-decreasing group.
In the multivariable adjusted model, the hazard ratio
(HR) for the moderate-consistent group indicated a 41%
increase in the mortality rate (HR = 1.41, 95% CI 1.36 to
1.47) relative to the high-consistent group (see Table 3).
However, patients in the poor-decreasing group experi-
enced a 6% decrease in mortality rate (HR = 0.94; 95% CI
0.90 to 0.99) relative to the reference (high-consistent)
group,. These results varied from those of the unadjusted
survival analysis. Whereas the unadjusted survival find-
ings showed that patients receiving consistently frequent
care had the greatest survival rate (Figure 3), the adjusted
model showed that patients in the poor-decreasing care
group had a lower mortality rate. Mortality also corre-
lated with age (increasing by 78% per decade) and
comorbid disease burden. For each unit increase in the
Charlson and Selim scores, mortality increased by 21%
and 1%, respectively.
Table 1 Baseline characteristics of veterans with
schizophrenia aged 50 years or older (n = 49,173).
Parameter
Age, years1 59.6 ± 9.2 (56.0) (50 to 102)
SCI1 3.82 ± 2.2 (3.0) (1 to 16)







Marital status, n (%)





Priority 1 status 26,187 (53.3)









Congestive heart failure 1,595 (3.2)
COPD 7,482 (15.2)




Cardiac arrhythmias 1,940 (3.9)
Lower back pain 5,872 (11.9)
Myocardial infarction 1,147 (2.3)
Nicotine dependence 11,429 (23.2)
Obesity 5,920 (12.0)
Peripheral vascular disease 1,399 (2.8)
Chronic renal disease 1,344 (2.7)
Stroke 1,422 (2.9)
Urinary tract infection 1,484 (3.0)
Mental health disorders
Alcohol abuse or dependence 6,448 (13.1)
Anxiety 4,221 (8.6)
Bipolar disorder 5,998 (12.2)
Depression 10,488 (21.3)
PTSD 6,075 (12.4)
Abbreviations: CCS, Charlson Comorbidity Score; COPD, chronic obstructive
pulmonary disease; SCI, Selim Comorbidity Index; PTSD, post-traumatic stress
disorder.
1Data are mean ± SD (median) (range).
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Figure 1 Proportion of patients with schizophrenia receiving each type of care, stratified by fiscal year (n = 49,173).
Figure 2 Cluster trajectories of patients with schizophrenia receiving care, stratified by fiscal year (n = 49,173).
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Table 2 Baseline patient characteristics by clusters (n = 49,173).
high-consistent care, n = 20,854 Moderate-consistent care, n = 18,218 poor-decreasing care, n = 10,101
Age, years1 57.8 ± 8.0 60.3 ± 9.5 62.2 ± 10.1
SCI1 4.37 ± 2.3 3.48 ± 2.1 3.31 ± 2.1
CCS1 1.16 ± 1.6 0.91 ± 1.5 0.82 ± 1.3
Ethnicity, n (%)
White 13,602 (65.2) 12,069 (66.3) 6,574 (65.1)
Black 6,529 (31.3) 5,000 (27.5) 2,588 (25.6)
Other 289 (1.4) 242 (1.3) 127 (1.3)
Hispanic 2,518 (12.1) 1,513 (8.3) 560 (5.5)
Unknown 434 (2.1) 907 (5.0) 812 (8.0)
Marital status
Single (never married) 7,548 (36.2) 7,243 (39.8) 4,459 (44.1)
Married 6,317 (30.3) 4,937 (27.1) 2,079 (20.6)
Divorced 6,049 (29.0) 4,945 (27.1) 2,869 (28.4)
Widowed 703 (3.4) 765 (4.2) 492 (4.9)
Priority 1 status 12,232 (58.7) 9,616 (52.8) 4,339 (43.0)
Mortality 5,491 (26.3) 6,585 (36.2) 3,126 (31.0)
Antipsychotic adherence
Good 6,640 (31.8) 4,737 (26.0) 1,709 (16.9)
Poor 11,700 (56.1) 10,203 (56.0) 5,446 (53.9)
Irregular 2,514 (12.1) 3,278 (18.0) 2,946 (29.2)
Medical/physical diagnoses
Anemia 1,348 (6.5) 1,071 (5.9) 516 (5.1)
Angina 648 (3.1) 348 (1.9) 152 (1.5)
Cancer 1,481 (7.1) 1,237 (6.8) 451 (4.5)
Cataracts 2,932 (14.1) 1,555 (8.5) 792 (7.8)
Congestive heart failure 715 (3.4) 613 (3.4) 267 (2.6)
COPD 3,526 (16.9) 2,753 (15.1) 1,203 (11.9)
Diabetes mellitus per Selim 6,724 (32.2) 3,217 (17.7) 1,482 (14.7)
Hepatitis 1,676 (8.0) 796 (4.4) 314 (3.1)
Hypertension 10,876 (52.2) 7,128 (39.1) 3,058 (30.3)
Dyslipidemia 7,999 (38.4) 4,547 (25.0) 1,601 (15.9)
Cardiac arrhythmias 962 (4.6) 660 (3.6) 318 (3.2)
Lower back pain 3,269 (15.7) 1,835 (10.1) 768 (7.6)
Myocardial infarction 528 (2.5) 431 (2.4) 188 (1.9)
Nicotine dependence 5,897 (28.3) 3,770 (20.7) 1,762 (17.4)
Obesity 3,614 (17.3) 1,649 (9.1) 657 (6.5)
Peripheral vascular disease 658 (3.2) 485 (2.7) 256 (2.5)
Chronic renal disease 616 (3.0) 503 (2.8) 225 (2.2)
Stroke 596 (2.9) 488 (2.7) 338 (3.4)
Urinary tract infection 662 (3.2) 548 (3.0) 274 (2.7)
Mental health disorders
Alcohol 3,507 (16.8) 1,859 (10.2) 1,082 (10.7)
Anxiety 2,210 (10.6) 1,357 (7.5) 654 (6.5)
Bipolar disorder 3,163 (15.2) 1,796 (9.9) 1,039 (10.3)
Depression 5,548 (26.6) 3,199 (17.6) 1,741 (17.2)
PTSD 3,541 (17.0) 1,744 (9.6) 790 (7.8)
Abbreviations: CCS, Charlson Comorbidity Score; COPD, chronic obstructive pulmonary disease; SCI, Selim Comorbidity Index; PTSD, post-traumatic stress disorder.
1Data are mean ± SD (median) (range).
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Discussion
For older male outpatients with schizophrenia, our analyses
support a modest longitudinal association over an 8-year
period between a greater scope of guideline-concordant
care and survival. However, patients in the group who
received the least comprehensive guideline-concordant
care had better adjusted odds of survival than those
receiving high or moderate levels of care, although the ben-
efit relative to those with high-consistent care was small.
This group was characterized by lower comorbidity, older
age (but a larger age range), and fewer VA priority 1 veter-
ans (those with a high level of disability), thus apparently
less need for care. The mechanisms by which this survival
benefit might accrue include access to care being
Table 3 Cox proportional-hazards model for mortality (n = 49,173).
Predictor Estimate, mean ± SE HR (95% CI) P value
Age (in decades) 0.58 (0.01) 1.78 (1.75 to 1.81) <0.01
CCS 0.19 (<0.01) 1.21 (1.20 to 1.23) <0.01
SCI total 0.01 (<0.01) 1.01 (1.00 to 1.02) <0.01
Priority 1 status -0.09 (0.02) 0.91 (0.89 to 0.94) <0.01
AP adherence
Poor 0.08 (0.02) 1.08 (1.04 to 1.12) <0.01
Irregular 0.15 (0.02) 1.16 (1.10 to 1.21) <0.01
Type of care
Moderate-consistent 0.35 (0.02) 1.41 (1.36 to 1.47) <0.01
Poor-decreasing -0.06 (0.02) 0.94 (0.90 to 0.99) 0.02
Abbreviations: AP, Antipsychotic; CCS, Charlson Comorbidity Score; HR, hazard ratio; SCI, Selim Comorbidity Index.
Figure 3 Survival function of the three patterns of care (n = 49,173).
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selectively used, emphasis on prevention and early disease
management being common in primary care, and a focus
on necessary care [30]. Possibly these patients also avoided
excess medical care that might itself carry increased risk to
their well-being through iatrogenic mechanisms. Moreover,
patients in the poor-decreasing care group had less comor-
bidity, which is known to account for half the excess mor-
tality of persons with schizophrenia [31]. Their relatively
lower rates of cardiovascular diagnoses may account for
some of the findings and the lower levels of care.
Interestingly, this sample of veterans with schizophre-
nia received on average only 4.8 out of the 11 care types
examined. The patient’s burden of illness translates into
the healthcare system’s challenge of providing appropri-
ate preventive services; difficult care coordination for
patients with the diminished self-care capacity or cogni-
tive deficits common with schizophrenia may account for
this modest level of guideline-concordant care [32]. Least
common were visits for nicotine dependence, weight
management, drug/alcohol dependency infectious dis-
eases, eye care, and group psychotherapy. Over time, pos-
sibly due to aging, the percentage of patients receiving
cardiovascular and eye care tended to increase, which is
appropriate given the age-related nature of cardiovascular
and eye disorders. The failure to address weight manage-
ment is unfortunate, as this common condition potenti-
ates much cardiovascular disease. Other research on VA
patients with schizophrenia noted no disparities in
receipt of obesity care practices, but did note a generally
low level of weight management [33].
Of note, the proportion of patients receiving mental
health treatment (psychiatric consults for medication
management, and individual, family, and group therapy)
gradually decreased over time. Regarding medication
management, this may indicate diminishing use of anti-
psychotic agents in later life. A 2004 review suggested
that older persons with schizophrenia do not need fewer
medications, but a recent analysis suggests that they may
require lower doses or antipsychotics or none at all
[34,35]. Nevertheless, patients who used antipsychotics
consistently had a longer survival than those with poor
or inconsistent use, seemingly in line with the report by
Maher and Theodore, who found that appropriate anti-
psychotic use was not associated with increased mortality
[36]. The results from liver and renal function tests, often
used to monitor adverse drug effects, were generally high
[37]. Families involved in the care of these patients
should be mindful of the need to work closely with care
providers regarding medication options (for example,
dose adjustment, possible medication changes to limit
weight gain). Psychological counseling, particularly family
counseling, can improve illness insight and thence treat-
ment adherence, and also improve family functioning
[38]. The declines in mental health counseling merit
investigation into the client and family need for and ben-
efit from these services.
Patients who fail to come in for outpatient care for 12
months or more [17] experience heightened risk of
death, whether through increased risk due to heart dis-
ease [39], adverse effects of antipsychotics on cardiovas-
cular functioning and metabolic regulation [40,41], or
increased risk of liver or renal disease [16]. Over time,
the proportion of patients receiving renal/liver function
care and psychiatric medication management in the
moderate-consistent and poor-decreasing care groups
gradually declined. Receiving liver function screening,
especially for patients with liver disease, is associated
with appropriate treatment and longer survival [42].
Insufficient monitoring would provide fewer opportu-
nities to make adjustments in medication regimens
including hepatotoxic medications, and patients are
likely to continue using psychotropic medications that
exacerbate liver problems if poor liver functioning goes
undetected. Accordingly, providers and family caretakers
should be vigilant when patients decrease their health-
care visits over time or miss appointments.
As this is perhaps the first study to examine the asso-
ciation of comprehensive guideline-based care with sur-
vival for older male patients with schizophrenia, our
findings suggest that greater adherence to screening and
treatment recommendations is crucial to patient survi-
val, and may reduce premature mortality. Additionally,
early detection and treatment of incipient problems is
likely to produce greater returns in terms of quality of
life for older patients with schizophrenia, and to reduce
the strain of caretaking for the older patient’s social net-
work. It is important for mental and primary healthcare
practitioners to coordinate care efforts and improve
overall adherence to these treatment guidelines. These
patients may benefit from aggressive outreach and use
of a patient-centered medical home to improve care
coordination and treatment adherence.
Limitations and strengths
This study relied on administrative data, thus severity
ratings of psychiatric or medical illnesses were not avail-
able and nor were quality-of-life assessments. Medicare
and other out-of-system data were unavailable, thus any
such services received were not captured by our study
methods [23]. Future research linking VA with Medicare
data to assess guideline-concordant care could deter-
mine the extent of bias introduced in our results by reli-
ance on a single healthcare system for those persons
covered by Medicare. For example, patients in the poor-
decreasing care cluster may have been more likely than
others to seek healthcare services outside the VA after
the baseline year, as many were reaching the age of 62
(early eligibility) or 65 (usual eligibility) years during the
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period of observation. On the other hand, patients with
serious mental illness tend to stay within the VA [43].
Although a high proportion of patients received family
counseling, it is uncertain whether this translated into
evidenced-based family services for schizophrenia, con-
sidering that previous studies have identified low rates
of such care [44]. Of note, the present study focused on
male veterans age 50 years or older, therefore results
cannot be generalized to women or younger patients.
VA patients tend to have lower incomes and more
health problems than the general population in the
USA, which may affect their need for care and the
breadth of healthcare options available to them [45].
The strengths of the study include its large scale and
longitudinal design, which enabled us to follow patients
over an 8-year period, and an innovative approach map-
ping the treatment recommendations from APA guide-
lines onto the indicators of care received. The study
addressed a crucial and serious healthcare problem,
namely, premature mortality among patients with schi-
zophrenia. We were careful to include preventive care,
such as screenings for common medical and psychiatric
comorbidities, as well as treatment for these conditions.
A further strength was the use of cluster analysis, which
enabled a practical and interpretable comparison of
patient groups characterized by different patterns of
care over time.
Future research on the effects of preventive care for
individuals with schizophrenia is needed to replicate and
extend the results of this study. Studies are needed in
other healthcare systems, and including people who lack
access to consistent sources of care. Also of value would
be an examination of the relative importance of the types
of recommended care in reducing premature mortality.
For example, through family counseling, family members
of patients with schizophrenia may be more likely to
assist with medical adherence and coordination. This
may be especially important when patients with schizo-
phrenia require complex coordinated care, which may be
difficult to manage.
Conclusions
Older veterans with schizophrenia received only a mod-
est number of the recommended annual health care ser-
vices in the VA. Patients receiving consistent and more
comprehensive guideline-concordant care had better sur-
vival than those receiving moderate-consistent levels of
care, even though they had more illnesses. These findings
highlight the importance of the quality and comprehen-
siveness of guideline-concordant preventive healthcare
for older patients with schizophrenia, augmenting the lit-
erature, which has previously shown that receipt of pri-
mary care correlates with survival [17,46,47]. Healthcare
systems should consider ways to better engage patients
and their families in coordinated healthcare services. Bar-
riers to access, treatment needs, and treatment prefer-
ences must be addressed creatively to maintain the
highest quality of care for our most vulnerable patients.
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